SolasCure has initiated a new Phase II clinical trial, CLEANVLU2, to further the development of its investigational product, ...

SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for ...

The gel is designed to be a 'safe' debrider suitable ... in addressing all aspects of wound bed preparation, including debridement. As part of the community service, the trial is being conducted ...